hrcak mascot   Srce   HID

Pregledni rad
https://doi.org/10.11613/BM.2013.020

Pharmacogenetics and personalized treatment of type 2 diabetes

Sabina Semiz   ORCID icon orcid.org/0000-0003-2629-4660 ; 1Department of Biochemistry and Clinical Analysis, Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina 2Faculty of Engineering and Natural Sciences, International University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Tanja Dujic ; Department of Biochemistry and Clinical Analysis, Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Adlija Causevic ; Department of Biochemistry and Clinical Analysis, Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina

Puni tekst: engleski, pdf (210 KB) str. 154-171 preuzimanja: 640* citiraj
APA 6th Edition
Semiz, S., Dujic, T. i Causevic, A. (2013). Pharmacogenetics and personalized treatment of type 2 diabetes. Biochemia Medica, 23 (2), 154-171. https://doi.org/10.11613/BM.2013.020
MLA 8th Edition
Semiz, Sabina, et al. "Pharmacogenetics and personalized treatment of type 2 diabetes." Biochemia Medica, vol. 23, br. 2, 2013, str. 154-171. https://doi.org/10.11613/BM.2013.020. Citirano 20.01.2021.
Chicago 17th Edition
Semiz, Sabina, Tanja Dujic i Adlija Causevic. "Pharmacogenetics and personalized treatment of type 2 diabetes." Biochemia Medica 23, br. 2 (2013): 154-171. https://doi.org/10.11613/BM.2013.020
Harvard
Semiz, S., Dujic, T., i Causevic, A. (2013). 'Pharmacogenetics and personalized treatment of type 2 diabetes', Biochemia Medica, 23(2), str. 154-171. https://doi.org/10.11613/BM.2013.020
Vancouver
Semiz S, Dujic T, Causevic A. Pharmacogenetics and personalized treatment of type 2 diabetes. Biochemia Medica [Internet]. 2013 [pristupljeno 20.01.2021.];23(2):154-171. https://doi.org/10.11613/BM.2013.020
IEEE
S. Semiz, T. Dujic i A. Causevic, "Pharmacogenetics and personalized treatment of type 2 diabetes", Biochemia Medica, vol.23, br. 2, str. 154-171, 2013. [Online]. https://doi.org/10.11613/BM.2013.020

Sažetak
Type 2 diabetes mellitus (T2DM) is a worldwide epidemic with considerable health and economic consequences. T2DM patients are often treated with more than one drug, including oral antidiabetic drugs (OAD) and drugs used to treat diabetic complications, such as dyslipidemia and hypertension. If genetic testing could be employed to predict treatment outcome, appropriate measures could be ta-ken to treat T2DM more efficiently. Here we provide a review of pharmacogenetic studies focused on OAD and a role of common drug-metabolizing enzymes (DME) and drug-transporters (DT) variants in therapy outcomes. For example, genetic variations of several membrane transporters, including SLC22A1/2 and SLC47A1/2 genes, are implicated in the highly variable glycemic response to met-formin, a first-line drug used to treat newly diagnosed T2DM. Furthermore, cytochrome P450 (CYP) enzymes are implicated in variation of sulphonylurea and meglitinide metabolism. Additional variants related to drug target and diabetes risk genes have been also linked to interindividual differences in the efficacy and toxicity of OAD. Thus, in addition to promoting safe and cost-effective individualized diabetes treatment, pharmacogenomics has a great potential to complement current efforts to optimi-ze treatment of diabetes and lead towards its effective and personalized care.

Ključne riječi
type 2 diabetes mellitus; pharmacogenomics; pharmacogenetics; oral antidiabetic drugs; personalized medicine

Hrčak ID: 103792

URI
https://hrcak.srce.hr/103792

Posjeta: 1.067 *